Breaking News, Trials & Filings

Almac Validates ColDx Assay

Out-licenses test to Precision Therapeutics

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Almac’s Diagnostics business unit has validated its ColDx signature for stage II colon cancer recurrence. Almac has out-licensed the test to Precision Therapeutics, Inc. for further independent validation and commercialization in the U.S. The study, performed by Precision Therapeutics in conjunction with the Alliance for Clinical Trials in Oncology, demonstrates that the ColDx assay is a significant, independent predictor of recurrence-free interval (RFI) in stage II colon cancer.   The independ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters